Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2026)

Adaptive Biotechnologies has disclosed Gross Profit across 9 years of filings, most recently posting $51.4 million for Q2 2026.

• In Q2 2026, Gross Profit rose 25.7% year-over-year to $51.4 million; the TTM figure through Jun 2026 stood at $232.8 million (up 71.8% YoY), while the FY2025 annual figure was $205.6 million, up 92.39% from the prior year.
• Gross Profit came in at $51.4 million for Q2 2026 at Adaptive Biotechnologies, down from $52.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $75.8 million in Q3 2025 to a low of $18.6 million in Q3 2023.
• Average Gross Profit over 5 years is $35.5 million, with a median of $30.7 million recorded in 2022.
• Year-over-year, Gross Profit tumbled 43.59% in 2023 and soared 154.69% in 2025.
• Over 5 years, Gross Profit stood at $38.6 million in 2022, then sank by 32.22% to $26.2 million in 2023, then increased by 12.4% to $29.4 million in 2024, then jumped by 81.74% to $53.5 million in 2025, then decreased by 3.87% to $51.4 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $51.4 million in Q2 2026, $52.2 million in Q1 2026, and $53.5 million in Q4 2025.